LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
25 funds hold it · Insiders net selling
Net selling: insiders sold $11M and bought $0 on the open market in 90 days (SEC Form 4). Congress: net buying of $2K to $30K in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Nov 4, 2026
Period ending
Sep 30, 2026
Earnings per share
-$1.40 expected
Estimates as of Nov 10, 2026
EPS expected
-$1.56 to -$0.90
Revenue expected
17 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Nov 4, 2026 | -$1.37est. -$1.40 | +2.39%beat | $47.6MSEC filing | +2356.5%from $1.9M |
| Jun 30, 2026Reported Aug 6, 2026 | -$1.50est. -$1.60 | +6.30%beat | $28.6MSEC filing | -57.1%from $66.8M |
| Mar 31, 2026Reported May 5, 2026 | -$1.67est. -$1.65 | -1.34%miss | $19.4MSEC filing | +1125.8%from $1.6M |
| Dec 31, 2025Reported Feb 24, 2026 | -$1.50est. -$1.37 | -9.67%miss | $17.8MAlpha Vantage | +4.9%from $16.9M |
| Sep 30, 2025Reported Nov 5, 2025 | -$1.54est. -$1.59 | +3.14%beat | $1.9MSEC filing | +318.1%from $463.0K |
| Jun 30, 2025Reported Aug 7, 2025 | -$1.12est. -$1.34 | +16.42%beat | $66.8MSEC filing | +26714.9%from $249.0K |
| Mar 31, 2025Reported May 6, 2025 | -$1.36est. -$1.36 | +0.00%in line | $1.6MSEC filing | +89.1%from $835.0K |
| Dec 31, 2024Reported Feb 27, 2025 | -$1.26est. -$1.17 | -7.33%miss | $16.9MAlpha Vantage | +912.4%from $1.7M |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $17.8M | $19.4M | $28.6M | $47.6M |
| Cost of what it sold | $2.9M | $2.4M | $2.7M | $2.2M |
| Gross profit | $14.9M | $17.0M | $25.9M | $45.3M |
| What it spent | ||||
| Research and development | $101.5M | $95.5M | $97.8M | $99.3M |
| Sales and admin | $91.7M | $104.9M | $104.4M | $113.1M |
| Other operating costs | — | — | $2.9M | — |
| Total operating expenses | $193.3M | $200.6M | $205.1M | $212.4M |
| What was left | ||||
| Operating profit | -$178.4M | -$183.6M | -$179.2M | -$167.1M |
| Interest on debt | $30.3M | $33.3M | $34.8M | $38.5M |
| Profit before tax | -$183.0M | -$206.0M | -$198.8M | -$190.1M |
| Net profit | -$183.0M | -$206.0M | -$198.8M | -$190.1M |
| EBITDA | -$180.2M | -$169.3M | -$195.1M | -$147.9M |
This stock is under pressure.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage leans bullish
B Lynne Parshall proposes selling 5,000 Cytokinetics (CYTK) shares.
NeutralNov 9Temporary heart-function drops affected 12 of 410 patients; none were linked to heart-failure stays or deaths.
Leans bullishNov 9Cytokinetics Announces Additional Data Related to Aficamten Presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026
BullishNov 9Cytokinetics, Incorporated (NASDAQ:CYTK) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year
Leans bullishNov 9Cytokinetics, Incorporated 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:CYTK) 2026-11-08
NeutralNov 8Precision Trading with Cytokinetics Incorporated (CYTK) Risk Zones
Leans bearishNov 6Cytokinetics (CYTK) Stock Looks Hard To Judge On Book Value
NeutralNov 6Cytokinetics stock hits 52-week low at 58.0 USD
Leans bearishNov 524 macro signals shaping CYTK right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
